NASDAQ:GMTX Gemini Therapeutics (GMTX) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free GMTX Stock Alerts $26.52 -0.78 (-2.86%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$25.86▼$27.0450-Day Range$26.52▼$75.3252-Week Range$1.16▼$14.10Volume314,536 shsAverage Volume189,291 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Gemini Therapeutics alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Gemini Therapeutics Stock (NASDAQ:GMTX)Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Read More GMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMTX Stock News HeadlinesApril 17, 2024 | seekingalpha.comGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysFebruary 26, 2024 | washingtonpost.comGoogle takes down Gemini AI image generator. Here’s what you need to know.April 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 26, 2024 | nypost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoJune 24, 2023 | benzinga.com(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson FistelJune 1, 2023 | barrons.comBronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) InvestigationJanuary 13, 2023 | markets.businessinsider.comThe Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalatesJanuary 1, 2023 | usatoday.comGemini HoroscopeApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.December 27, 2022 | finance.yahoo.comDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic ProtoporphyriaOctober 31, 2022 | finance.yahoo.comDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)September 27, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, PBFX, EVOP, GMTXSeptember 26, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFYSeptember 16, 2022 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZSeptember 6, 2022 | markets.businessinsider.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFEAugust 25, 2022 | apnews.comThe M&A Class Action Firm Announces the Investigation of Gemini Therapeutics, Inc. – GMTXAugust 24, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing InvestigationsAugust 12, 2022 | apnews.comGEMINI THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GMTX and Encourages Investors to Contact the FirmAugust 12, 2022 | marketwatch.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. MergerAugust 11, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Gemini Therapeutics, Inc.August 11, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZAugust 11, 2022 | apnews.comGMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to ShareholdersAugust 10, 2022 | apnews.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Gemini Therapeutics, Inc. (Nasdaq – GMTX)August 10, 2022 | finance.yahoo.comBlood disorder startup goes public by merging with embattled biotechAugust 10, 2022 | seekingalpha.comGemini stock soars 35% on merger with Disc Medicine in all-stock dealAugust 10, 2022 | nasdaq.comGemini Therapeutics, Disc Medicine Announce All-stock MergerAugust 10, 2022 | finance.yahoo.comGemini Therapeutics and Disc Medicine Announce Merger AgreementSee More Headlines Receive GMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GMTX CUSIPN/A CIK1816736 Webwww.geminitherapeutics.com Phone415-877-4887FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.78% Return on Assets-35.88% Debt Debt-to-Equity RatioN/A Current Ratio71.49 Quick Ratio71.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book9.18Miscellaneous Outstanding Shares43,328,000Free Float37,739,000Market Cap$1.15 billion OptionableNot Optionable Beta-0.12 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Georges Gemayel C.F.A. (Age 62)Ph.D., Interim Pres & CEO and Exec. Chairperson Comp: $256.73kMr. Brian Piekos (Age 46)Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer Comp: $549.73kMr. Jason Patrick Meyenburg M.B.A. (Age 44)M.D., Advisor Comp: $715.96kMr. Patrick Truesdell (Age 41)VP of Fin. & Controller Key CompetitorsCollegium PharmaceuticalNASDAQ:COLLAbCellera BiologicsNASDAQ:ABCLDeciphera PharmaceuticalsNASDAQ:DCPHPieris PharmaceuticalsNASDAQ:PIRSMirum PharmaceuticalsNASDAQ:MIRMView All Competitors GMTX Stock Analysis - Frequently Asked Questions How have GMTX shares performed in 2024? Gemini Therapeutics' stock was trading at $57.76 at the start of the year. Since then, GMTX shares have decreased by 54.1% and is now trading at $26.52. View the best growth stocks for 2024 here. How were Gemini Therapeutics' earnings last quarter? Gemini Therapeutics, Inc. (NASDAQ:GMTX) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04. How do I buy shares of Gemini Therapeutics? Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GMTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
